Ekso Bionics Holdings Inc. reported financial results for Q2 2025, with revenue at $2.1 million, a decrease from $5.0 million in Q2 2024. Gross profit was $0.8 million, with a 40% margin. Operating expenses totaled $4.7 million. Net loss was $2.7 million. Cash and restricted cash stood at $5.2 million as of June 30, 2025.

Recent accomplishments include partnerships with Bionic P&O and NVIDIA Connect. Ekso Bionics launched eksoUniversity for physical therapists. CEO Scott Davis mentioned short-term delays in Enterprise Health sales but expects growth in Personal Health products, which increased by over 50% year-over-year in the first half of 2025.

The Company invites all interested parties to a conference call today at 1:30 p.m. PT / 4:30 p.m. ET to discuss financial results and recent business developments. Ekso Bionics is known for its exoskeleton solutions that enhance strength, endurance, and mobility in medical and industrial applications. The Company is listed on Nasdaq under the symbol “EKSO.”

Ekso Bionics’ Q2 2025 financial results showed revenue of $2.1 million, gross profit of $0.8 million, and net loss of $2.7 million. Operating expenses totaled $4.7 million. Cash and restricted cash stood at $5.2 million as of June 30, 2025. The Company focuses on advancing health and quality of life through robotic technologies.

Read more at GlobeNewswire.: Ekso Bionics Reports Second Quarter 2025 Financial Results